knowledge -WSS

knowledge

author：hotspot 2025-10-01 18:24:11 - browse：423

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： As AI regulations shape up, health tech startups beg for clarity

WSS

Ukraine and a new approach to mental health in war

Microbiome research is starting to find links to chronic diseases

Why are Kaiser Permanente staff considering a strike?

Changes to biosimilar regulatory framework must prioritize patients

Microbiome research is starting to find links to chronic diseases

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

leisure time

knowledge

entertainment

Jerome Adams on the need for new antivirals for Covid

Congress may force more Covid

BioMarin wins approval for gene therapy to treat hemophilia A

Reporting on presidential health from Reagan to Trump and Biden

Medical leaders decry Supreme Court decision on affirmative action

Readout LOUD podcast: Pharma in Washington, Alnylam, and Gilead

Medical leaders decry Supreme Court decision on affirmative action

CDC advisers recommend seasonal use of Pfizer RSV shot

At least 13 dead in Texas as scorching temps continue

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Wikipedia

Medicare Advantage enrollment hits roughly 33.4 million

Drug for rare kidney disease narrowly misses mark in clinical trial

WATCH: Why do our ears pop?

Hospitals are piloting generative AI tools as regulators play catch

Experts study whether long Covid risk adds up with each reinfection

Hospitals are piloting generative AI tools as regulators play catch

hotspot

explore

knowledge

focus